Eli Lilly Q3 Revenue Rises 39% to $24.4 Billion, Raises 2026 Guidance
Eli Lilly reported Q3 2026 revenue of $24.4B, up 39% YoY, with net income of $6.5B. The company raised 2026 revenue guidance to $91B-$92B and updated non-GAAP EPS to $35.00-$36.00. Growth was driven by Mounjaro, Zepbound, and new product launches, including FDA approvals for Mounjaro and Onswik.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to boost LLY's valuation and may influence peer stocks in the biotech sector.
Market read
Large‑cap pharma earnings with raised guidance provide a clear trading catalyst for LLY and sector peers.
What to watch
Potential regulatory delays for new indications or competitive pressure from emerging biosimilars could temper upside.
Background
Eli Lilly's Q3 results highlight continued growth in its diabetes, obesity, and oncology pipelines, with several FDA approvals and pipeline advancements.
Ticker impact
Eli Lilly reported Q3 2026 revenue up 39% YoY and raised its 2026 revenue guidance to $91‑$92 B and non‑GAAP EPS guidance to $35‑$36, a fresh earnings and guidance release.
upward pressure as investors price in higher revenue and earnings expectations
The company beat prior guidance and lifted its full‑year targets, which historically triggers a price rally for large‑cap pharma stocks.
Market effects
Biopharma sector may see a lift as Lilly's strong guidance reinforces demand for diabetes and obesity drugs.
U.S. markets could open higher on the back of the earnings beat.
Global investors tracking pharma earnings will adjust expectations for related peers.
Counterpoint
If the guidance is overly optimistic, a future miss could trigger a sharp correction.
Key entities
- companyEli Lilly
U.S. pharmaceutical company reporting Q3 2026 results.
